Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

Once one of the hottest brands in biotech, Patrick Soon-Sh­iong’s next-gen can­cer brain­child Nan­tK­west has tak­en its lumps in re­cent years with lit­tle to show from its nat­ur­al killer cell plat­form. Now, with his cell ther­a­py play Im­mu­ni­ty­Bio mov­ing much faster in the clin­ic, Soon-Sh­iong will merge the two com­pa­nies to­geth­er to stream­line their mar­ket as­pi­ra­tions.

Nan­tK­west will re­verse merge with Soon-Sh­iong’s Im­mu­ni­ty­Bio in a stock-for-stock trans­ac­tion to bring 11 late-stage nat­ur­al killer and cell ther­a­py can­di­dates for on­col­o­gy and in­fec­tious dis­eases un­der a sin­gle roof, the com­pa­nies said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER